

**WOMENS INTERAGENCY HIV STUDY
 INTENSIVE PK STUDY
 FORM PK01: ELIGIBILITY FORM**

**THIS FORM SHOULD BE COMPLETED AT THE WIHS CORE VISIT FOR ALL WIHS PARTICIPANTS
 (EXCEPT FOR THOSE ENROLLED AT THE LA WIHS SITE).**

SECTION A: GENERAL INFORMATION

- A1. PARTICIPANT ID: ENTER NUMBER HERE - - - -
 ONLY IF ID LABEL IS NOT AVAILABLE
- A2. WIHS STUDY VISIT #: _____
- A3. FORM VERSION: **04 / 01 / 09**
- A4. DATE OF COMPLETION: _____ / _____ / _____
 M D Y
- A5. INTERVIEWER'S INITIALS: _____

SECTION B: ELIGIBILITY

- B1. IS PARTICIPANT HIV-POSITIVE?
 YES..... 1
 NO..... 2 **PARTICIPANT IS INELIGIBLE FOR PK SUBSTUDY.
 SKIP TO B3.**

- B2. CHECK EACH ANTIRETROVIRAL MEDIATION BELOW THAT PARTICIPANT IS CURRENTLY TAKING. IF THE PARTICIPANT IS NOT ON ANY OF THESE MEDICATIONS, CHECK 'NONE OF THE ABOVE.'
- _____ Raltegravir (*Isentress*) (ELIGIBLE)
 _____ NONE OF THE ABOVE (INELIGIBLE)

NOTE: IF PARTICIPANT HAS COMPLETED AN INTENSIVE PK SUBSTUDY VISIT PREVIOUSLY FOR ONE OF THE TARGET MEDICATIONS ABOVE, SHE IS NOT ELIGIBLE TO ENROLL AGAIN FOR THE SAME MEDICATION. IN THIS CASE, "INELIGIBLE" SHOULD BE CIRCLED IN QUESTION B3. HOWEVER, IF SHE HAS COMPLETED A PRIOR PK VISIT FOR ONE TARGET MEDICATION AND IS NOW TAKING A DIFFERENT TARGET MEDICATION, SHE MAY ENROLL FOR THE NEW MEDICATION.

- B3. OUTCOME:
 ELIGIBLE, OKAY TO CALL TO SCHEDULE APPOINTMENT 1
 ELIGIBLE, DECLINED TO PARTICIPATE..... 2 (END)
 INELIGIBLE 3 (END)

- B4. CIRCLE THE GROUP TO WHICH PARTICIPANT BELONGS BASED ON ANTIRETROVIRALS CHECKED IN B2. GROUP
 Participant is on *Raltegravir* taken twice daily A

IF PARTICIPANT IS ELIGIBLE AND HAS CONSENTED TO ENROLL IN THE INTENSIVE PK STUDY, REFER HER FOR GCRC VISIT. AT GCRC VISIT, COMPLETE AND DATA ENTER FORM PKNOTI.

DO NOT DATA ENTER FORM PK01.